Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine, Auryxia® (ferric citrate) tablets. Patients have been and continue to be at the center of our 18-year corporate history.
Keryx established its corporate headquarters in Boston to support the U.S. launch of Auryxia. Joining Boston’s pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 185 full-time employees across Boston and our field team.